ZOGENIX, INC.
DelistedCIK 1375151fmd_0FX64T9QQEPJGNDR99N6D9W25QManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2009 to Dec 31, 2021, 48 periods
| Line item | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 44 | 33 | 29 | 27 | 29 | 10 | 0 | 4 | 14 | 82 |
| Cost of revenue | 19 | 21 | 5 | 0 | 0 | 11 | 0 | 0 | 1 | 5 |
| Net interest income | – | (7) | (3) | (3) | (3) | (3) | (0) | (0) | (4) | (15) |
| Gross profit | 25 | 12 | 24 | 27 | 29 | (1) | 0 | 4 | 13 | 77 |
| Research and development | 21 | 8 | 12 | 28 | 42 | 67 | 0 | 251 | 11 | 0 |
| Selling, general and administrative | 49 | 46 | 35 | 26 | 27 | 26 | 39 | 61 | 100 | 149 |
| Total operating expenses | 92 | 78 | (12) | 75 | 102 | 130 | 141 | – | – | – |
| Operating income | (47) | (45) | 41 | (48) | (73) | (120) | (141) | (430) | (248) | (224) |
| Interest expense | 10 | 7 | 3 | 3 | – | – | – | – | – | – |
| Interest and investment income | 0 | 0 | 0 | – | – | – | – | – | – | – |
| Other non-operating income (expense) | 0 | (28) | 20 | (10) | 3 | (6) | 17 | 10 | 22 | 11 |
| Income before taxes | (47) | (73) | 62 | (58) | (70) | (126) | (124) | (420) | (227) | (227) |
| Income tax expense | 0 | 0 | 0 | (16) | (1) | 0 | 0 | 0 | (17) | 0 |
| Net income from continuing operations | (47) | (73) | 61 | (42) | (69) | (126) | (124) | (420) | (209) | (227) |
| Net income | (47) | (81) | 9 | 26 | (70) | (127) | (124) | (420) | (209) | (227) |